Report cover image

Acute Myocardial Infarction Global Market Report 2025

Published Sep 10, 2025
Length 250 Pages
SKU # BRC20385905

Description

Acute Myocardial Infarction Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute myocardial infarction market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description:

Where is the largest and fastest growing market for acute myocardial infarction ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The acute myocardial infarction market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:1) By Type: ST-Elevation Myocardial Infarction (STEMI); Non-ST-Elevation Myocardial Infarction (NSTEMI)

2) By Treatment Type: Thrombolytic Therapy; Percutaneous Coronary Intervention (PCI); Coronary Artery Bypass Grafting (CABG); Medications

3) By Diagnosis Method: Electrocardiogram; Cardiac Biomarkers; Echocardiography; Coronary Angiography; Magnetic Resonance Imaging (MRI); Computed Tomography (CT) Scan

4) By Route Of Administration: Oral Route; Intravenous (IV) Route; Subcutaneous Route; Transdermal Route; Sublingual Route

5) By End User: Hospitals And Clinics; Ambulatory Surgical Centers; Specialty Cardiac Centers; Research Institutes

Subsegments:

1) ST-Elevation Myocardial Infarction (STEMI): Anterior ST-Elevation Myocardial Infarction (STEMI); Inferior ST-Elevation Myocardial Infarction (STEMI); Posterior ST-Elevation Myocardial Infarction (STEMI); Lateral ST-Elevation Myocardial Infarction (STEMI); Right Ventricular ST-Elevation Myocardial Infarction (STEMI); Extensive (Large) ST-Elevation Myocardial Infarction (STEMI)

2) Non-ST-Elevation Myocardial Infarction (NSTEMI): Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI); Partial Thickness Non-ST-Elevation Myocardial Infarction (NSTEMI); Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI); Silent Non-ST-Elevation Myocardial Infarction (NSTEMI); Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)

Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; Abbott Laboratories; Novartis AG; GSK plc; Eli Lilly and Company; Siemens Healthineers; Fujifilm Holdings Corporation; Koninklijke Philips N.V.; Boston Scientific Corporation; Daiichi Sankyo Company Limited; Terumo Corporation; MicroPort Scientific Corporation; Ionis Pharmaceuticals Inc.; CellProthera; Athersys Inc.; BioCardia Inc.; Serca Pharmaceuticals.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Table of Contents

250 Pages
1. Executive Summary
2. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Characteristics
3. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Trends And Strategies
4. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Growth Analysis And Strategic Analysis Framework
5.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Growth Rate Analysis
5.4. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Total Addressable Market (TAM)
6. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Segmentation
6.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Olaparib
Rucaparib
Niraparib
Talazoparib
Other Types
6.2. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ovarian Cancer
Breast Cancer
Prostate Cancer
Pancreatic Cancer
6.3. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Research Institutions
Other End-Users
6.5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BRCA-Mutated Cancers
HRD-Positive Cancers
Maintenance Therapy
6.6. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Rucaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ovarian Cancer
Prostate Cancer
Pancreatic Cancer
6.7. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Niraparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-Line Treatment
Recurrent Cancer Treatment
Late-Stage Cancer
6.8. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Breast Cancer
Germline BRCA-Mutated Tumors
Neoadjuvant Or Adjuvant Therapy
6.9. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Emerging PARP Inhibitors
Investigational Therapies
Novel Combinations
7. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Regional And Country Analysis
7.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
8.1. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
9.1. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
9.2. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
10.1. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
11.1. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
11.2. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
12.1. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
13.1. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
14.1. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
14.2. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
15.1. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
15.2. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
16.1. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
17.1. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
18.1. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
19.1. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
20.1. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
21.1. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
21.2. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
22.1. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
23.1. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
23.2. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
24.1. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
24.2. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
25.1. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
25.2. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
26.1. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
26.2. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
27.1. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
28.1. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
28.2. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
29.1. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
29.2. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Landscape And Company Profiles
30.1. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Landscape
30.2. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Other Major And Innovative Companies
31.1. AstraZeneca plc
31.2. Bristol-Myers Squibb Company
31.3. GSK plc
31.4. Takeda Pharmaceutical Company Limited
31.5. Boehringer Ingelheim
31.6. Vertex Pharmaceuticals Inc.
31.7. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
31.8. BeiGene LTD
31.9. Karyopharm Therapeutics Inc.
31.10. Clovis Oncology Inc.
31.11. Repare Therapeutics Inc.
31.12. Ribon Therapeutics
31.13. Artios Pharma
31.14. IMPACT Therapeutics Inc.
31.15. BiPar Sciences Inc.
32. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
34. Recent Developments In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market
35. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market High Potential Countries, Segments and Strategies
35.1 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Countries Offering Most New Opportunities
35.2 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Segments Offering Most New Opportunities
35.3 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.